BioTech 365

APRIL 22, 2021

Castle Biosciences Presents Data at the Dermatology Nurses’ Association 2021 Annual Convention Castle Biosciences Presents Data at the Dermatology Nurses’ Association 2021 Annual Convention FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #DNANurses–Castle Biosciences, Inc.

Dermatology 40

Dermatology Nurses Genome Genomics 40

The Pharma Data

JANUARY 24, 2021

National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes. Quantum Genomics launched its Phase III REFRESH trial in difficult-to-treat or resistant hypertension.

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

AUGUST 11, 2020

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Immune-Mediated Skin and Dermatologic Adverse Reactions. Serious Adverse Reactions.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. Immune-Mediated Skin and Dermatologic Adverse Reactions. Serious Adverse Reactions.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52